Onconova Therapeutics, Inc. Warrants
ONTXW
ONTXW was delisted on the 23rd of July, 2021.
5 hedge funds and large institutions have $121K invested in Onconova Therapeutics, Inc. Warrants in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
157% more capital invested
Capital invested by funds: $47K → $121K (+$74K)
25% more funds holding
Funds holding: 4 → 5 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$24 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.49K |
ONTXW Hedge Fund Activity: Q1 2019 in Review
5 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Onconova Therapeutics, Inc. Warrants (ONTXW) for Q1 2019, worth a combined $121K — up 157% from $47K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ONTXW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $11.2K. The largest seller was Sabby Management, cutting an estimated $2.49K.
- 5 institutional investors held Onconova Therapeutics, Inc. Warrants (ONTXW) as of Q1 2019, up from 4 in Q4 2018.
- Funds reported $121K of Onconova Therapeutics, Inc. Warrants stock for Q1 2019, up 157% quarter-over-quarter.
- 1 fund opened new Onconova Therapeutics, Inc. Warrants positions in Q1 2019 and 0 closed out, a net change of +1 holder.
- The largest Onconova Therapeutics, Inc. Warrants buyer in Q1 2019 was Susquehanna International Group, an estimated $11.2K added.
- The largest Onconova Therapeutics, Inc. Warrants seller in Q1 2019 was Sabby Management, an estimated $2.49K sold.
Based on aggregated 13F filings for Q1 2019.